Recent Finacing
Recent Raise
Nexvet Biopharma develops species-specific monoclonal antibody therapeutics for pets using its PETisation platform to convert human biologics, with pipelines in canine and feline pain, inflammation and dermatitis.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors